This 56-week, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of 3.0 mg liraglutide in 3,731 overweight or obese adults without type 2 diabetes. Participants received daily subcutaneous injections of liraglutide or placebo, alongside lifestyle counseling. At week 56, the liraglutide group achieved a mean weight loss of 8.4
